Work

Abstract CT145: A phase II, multicenter, open-label study (COMPASSION-26) of cadonilimab, a PD-1/CTLA-4 bispecific antibody,combined with chemotherapy (chemo) as first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC)

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct145

Authors: Wenming Wu, Xiafei Hong, Qi Xu, Gang Jin, Zhihua Li, He Tian, Heshui Wu, Yiping Mou, Baocai Xing, Dianrong Xiu, Zhifang Yao, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Zhejiang Cancer Hospital, Changhai Hospital, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Shandong Tumor Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, Zhejiang Provincial People's Hospital, Peking University Cancer Hospital, Peking University, Peking University Third Hospital

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154724152

Cites:

Cited by:

Related to: